by Hanna | Oct 8, 2024 | Blog Post
The Federal Trade Commission (FTC) and Department of Justice (DOJ)’s aggressive approach towards mergers and acquisitions (M&A) is deterring companies from pursuing deals, write Bloomberg Law reporters Justin Wise and Mahira Dayal – threatening even procompetitive...
by Hanna | Oct 2, 2024 | Blog Post, Innovations Advanced by M&A
This blog is another installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this...
by Hanna | Sep 18, 2024 | Blog Post
For life science companies of all sizes, competitive mergers and acquisitions (M&A) serve as a critical driver in bringing new and groundbreaking treatments and cures to market. In a recent article published in Concurrences Law and Economics, economists from...
by Hanna | Sep 11, 2024 | Blog Post
Protecting and promoting collaboration across the U.S. life sciences ecosystem remains a driving force in bringing new breakthroughs to patients, according to a recent report from the Center for Strategic and International Studies (CSIS). As the report’s authors...
by Hanna | Sep 4, 2024 | Blog Post
On a recent episode of the ABA Antitrust Podcast Our Curious Amalgam, Dr. Penka Kovacheva, Cornerstone Research Vice President and lead author of a paper recently published in Concurrences, “The Impact of Pharmaceutical M&A on Innovation,” discusses many ways in...
by Hanna | Aug 7, 2024 | Blog Post
A recent article from BioPharma Dive highlights the challenging landscape for biopharmaceutical initial public offerings (IPOs), and the critical role that mergers & acquisitions play in connecting promising innovations with the resources and investment needed to...
